ABOUT LOTTE BIOLOGICS
LOTTE Biologics is a global contract development and manufacturing organization delivering integrated biologics and bioconjugate services across the full product lifecycle. Our capabilities encompass phase-appropriate drug substance manufacturing for mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, and multispecific modalities, as well as fully integrated Antibody Conjugate manufacturing.
With a unified Dual Hub Service model spanning the United States and South Korea, we strengthen supply chain security, enable scalable manufacturing pathways, and uphold consistent quality across regions.
Our Full Spectrum Services:
- Development Services
- Clinical Manufacturing Services
- Commercial Manufacturing Services
- Antibody Conjugate Manufacturing
- Analytical Services
INDUSTRY INSIGHTS
-
![GettyImages-931069642 mAb, monoclonal antibodies]( "Linker Design Approaches To Improve ADC Stability And Activity")
ADC design choices shape efficacy and selectivity. Hydrophilic modifications are evaluated for their effects on cytotoxic activity, target specificity, and cell viability across multiple tumor models.
-
![Lotte Biologics Photo]( "Improvements In ADC Efficacy And Stability")
Antibody–drug conjugates link antibodies to potent toxins, but increased hydrophobicity impairs stability, manufacturing, and PK, spurring interest in hydrophilic linker strategies.
-
![Conductor directing symphony orchestra-GettyImages-490338206]( "Project Management: The Conductor Behind Every Successful CDMO Program")
Understand how elite CDMO project management acts as a conductor—integrating molecule expertise, rigorous readiness, and disciplined GMP execution to drive successful biologics manufacturing programs.
VIDEOS & WEBINARS
CONTACT INFORMATION
LOTTE Biologics
30th Floor, LOTTE World Tower, 300 Olympic-ro
Songpa-Gu, Seoul, 05551
KOREA, REPUBLIC OF
Contact: Nathalie Scott, Global Marketing Team
NEWS
- LOTTE BIOLOGICS Signs Letter Of Intent (LOI) For Strategic Collaboration With U.S.-Based Multinational Company That Has Also Presence And Operation In Japan And Taiwan
- LOTTE BIOLOGICS Signs Strategic Partnership Agreement With U.S.-Based Asimov
- Rakuten Medical And LOTTE Biologics Sign Manufacturing Agreement To Support Biopharmaceuticals In Global Oncology Program
- LOTTE BIOLOGICS Establishes Contract Manufacturing Partnership With A Leading U.S. Biopharmaceutical Company
- LOTTE BIOLOGICS Signs Antibody Manufacturing Contract With Ottimo Pharma
- LOTTE BIOLOGICS Begins Full-Scale Operation Of ADC Manufacturing Facility
BROCHURES
-
![GettyImages-1158724314-electorphoresis-hand-filling-cell]( "Syracuse Bio Campus: Every Detail. Built Around You")
The Syracuse Bio Campus offers U.S.-based mammalian production and bioconjugation, supporting development through commercial manufacturing with regulatory expertise and tailored solutions.
-
Single‑site ADC manufacturing integrates antibody production, conjugation, and quality systems to reduce complexity, accelerate timelines, and support scalable clinical‑to‑commercial development.
-
![GettyImages-2167502114 bispecific antibodies]( "Songdo Bio Campus: Advanced Manufacturing, Coming Summer 2026")
A new biomanufacturing campus in Incheon features automation, digital monitoring, flexible large-scale production, and 120kL capacity, with completion expected in 2026.
-
![GettyImages-2150276083-lab-mask-tablet-PPE-cleanroom]( "Tailored CDMO Solutions With Unmatched Quality")
Partner with a premier global CDMO to move from discovery to commercialization faster, powered by dual-site manufacturing, 20+ years of expertise, and advanced ADC conjugation.
